European Commission authorizes Aratana’s Galliprant
Co-promoter Elanco Animal Health is allowed to market the anti-inflammatory for dogs.
Galliprant, an anti-inflammatory drug developed by Aratana Therapeutics Inc., has been approved for European distribution.
Elanco Animal Health, which manufactures and markets Galliprant (grapiprant tablets) under a license from Aratana, reported Jan. 11 that the European Commission granted marketing authorization in the European Union. The decision came about two months after the European Medicine Agency’s Committee for Medicinal Products for Veterinary Use recommended approval.
Galliprant is indicated to treat pain and inflammation associated with mild to moderate osteoarthritis in dogs. The active ingredient, grapiprant, is formulated to block the EP4 receptor. The drug earned U.S. Food and Drug Administration approval in March 2016.
Aratana, based in Leawood, Kansas, also makes Entyce (capromorelin oral solution), an appetite stimulant for dogs, and Nocita (bupivacaine liposome injectable suspension), a local analgesia for use after cranial cruciate ligament surgery in dogs.
Elanco is headquartered in Greenfield, Indiana.